S&P 500
(1.02%) 5 099.96 points
Dow Jones
(0.40%) 38 240 points
Nasdaq
(2.03%) 15 928 points
Oil
(0.11%) $83.66
Gas
(-1.16%) $1.619
Gold
(0.30%) $2 349.60
Silver
(-0.43%) $27.52
Platinum
(0.42%) $924.40
USD/EUR
(0.32%) $0.935
USD/NOK
(0.67%) $11.02
USD/GBP
(0.13%) $0.800
USD/RUB
(-0.07%) $92.11

Realaus laiko atnaujinimai Enzo Biochem Inc [ENZ]

Birža: NYSE Sektorius: Healthcare Pramonė: Diagnostics & Research
Atnaujinta26 bal. 2024 @ 23:00

-1.87% $ 1.050

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 23:00):

Enzo Biochem, Inc., an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology...

Stats
Šios dienos apimtis 114 913
Vidutinė apimtis 109 219
Rinkos kapitalizacija 53.79M
EPS $0 ( 2024-03-19 )
Kita pelno data ( $0 ) 2024-06-12
Last Dividend $0.0470 ( 1995-06-29 )
Next Dividend $0 ( N/A )
P/E -2.23
ATR14 $0.00300 (0.29%)
Insider Trading
Date Person Action Amount type
2024-02-23 Cannon Kara Buy 150 000 Common Stock
2024-02-21 Cannon Kara Buy 10 640 Common Stock
2024-02-21 Cannon Kara Sell 5 823 Common Stock
2024-02-23 Eckert Patricia Buy 75 000 Stock Option (to acquire shares of Common Stock)
2024-01-31 Pully Steven J Buy 79 365 Common Stock
INSIDER POWER
88.53
Last 85 transactions
Buy: 4 325 861 | Sell: 177 248

Tūris Koreliacija

Ilgas: 0.27 (neutral)
Trumpas: -0.56 (weak negative)
Signal:(51.331) Neutral

Enzo Biochem Inc Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
YSAC0.906
TSQ0.849
HZN0.841
DTC0.828
CRD-A0.819
10 Labiausiai neigiamai susiję koreliacijos
FPEI-0.872
ASB-PE-0.868
CUBB-0.868
GL-0.855
FLR-0.852
NX-0.843
MBI-0.836
PQDI-0.832
BGSF-0.832
SPNT-PB-0.825

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Enzo Biochem Inc Koreliacija - Valiuta/Žaliavos

The country flag 0.00
( neutral )
The country flag 0.51
( weak )
The country flag 0.00
( neutral )
The country flag 0.00
( neutral )
The country flag 0.00
( neutral )
The country flag 0.16
( neutral )

Enzo Biochem Inc Finansinės ataskaitos

Annual 2023
Pajamos: $31.06M
Bruto pelnas: $11.57M (37.24 %)
EPS: $-1.270
FY 2023
Pajamos: $31.06M
Bruto pelnas: $11.57M (37.24 %)
EPS: $-1.270
FY 2022
Pajamos: $107.07M
Bruto pelnas: $41.97M (39.20 %)
EPS: $-0.460
FY 2021
Pajamos: $117.73M
Bruto pelnas: $53.58M (45.51 %)
EPS: $0.160

Financial Reports:

No articles found.

Enzo Biochem Inc Dividends

(Q3/22) (Q4/22) (Q1/23) (Q2/23) (Q3/23) (Q4/23) (Q1/24) (Q2/24) (Q3/24) (Q4/24)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)

Enzo Biochem Inc Dividend Information - No Dividend Player

Dividend Sustainability Score: 5.02 - average (34.50%) | Divividend Growth Potential Score: 0.366 - No dividend growth expected in the near future
Information
First Dividend $0.0470 1995-06-29
Last Dividend $0.0470 1995-06-29
Next Dividend $0 N/A
Payout Date 0000-00-00
Next Payout Date N/A
# dividends 1 --
Total Paid Out $0.0470 --
Avg. Dividend % Per Year 0.00% --
Score 0.82 --
Div. Sustainability Score 5.02
Div.Growth Potential Score 0.366
Div. Directional Score 2.69 --
Next Divdend (Est)
(2024-04-28)
$0 Estimate 0.00 %
Dividend Stability
0.00 Very Bad
Dividend Score
0.82
Pay Frequency
Insufficient data to determine frequency
Yearly Payout
Year Amount Yield
1995 $0.0470 0.58%
1996 $0 0.00%
1997 $0 0.00%
1998 $0 0.00%
1999 $0 0.00%
2000 $0 0.00%
2001 $0 0.00%
2002 $0 0.00%
2003 $0 0.00%
2004 $0 0.00%
2005 $0 0.00%
2006 $0 0.00%
2007 $0 0.00%
2008 $0 0.00%
2009 $0 0.00%
2010 $0 0.00%
2011 $0 0.00%
2012 $0 0.00%
2013 $0 0.00%
2014 $0 0.00%
2015 $0 0.00%
2016 $0 0.00%
2017 $0 0.00%
2018 $0 0.00%
2019 $0 0.00%
2020 $0 0.00%
2021 $0 0.00%
2022 $0 0.00%
2023 $0 0.00%
2024 $0 0.00%

Dividend Commentary

With a moderate Dividend Sustainability Score (DSS), the company may sustain its dividends, but continuous monitoring is advised for any financial shifts. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NYSE

Symbol Title Last dividend Frequency Years Dividend Yearly Dividend Score
LOMA Dividend Knight 2023-06-30 Quarterly 2 5.23% 8.53
KIO Dividend Royal 2023-12-14 Monthly 12 7.05% 8.50
NCZ Dividend Royal 2024-02-09 Monthly 22 7.79% 8.50
SCM Dividend King 2023-12-15 Monthly 13 7.08% 8.50
SJT Dividend Royal 2023-11-29 Monthly 39 12.52% 8.50
GOF Dividend Royal 2023-11-14 Monthly 18 8.03% 8.50
SRV Dividend Royal 2023-12-04 Monthly 18 7.53% 8.50
VGI Dividend Royal 2024-02-09 Monthly 13 7.36% 8.50
JQC Dividend Royal 2023-11-14 Monthly 22 6.56% 8.50
PHK Dividend Royal 2023-11-10 Monthly 22 6.88% 8.50

Dividend Sustainability Score (DSS)

RatioActual ValueWeightNormalized ValueScoreRange
netProfitMarginTTM2.581.50010.0010.00[0 - 0.5]
returnOnAssetsTTM0.3331.20010.0010.00[0 - 0.3]
returnOnEquityTTM0.5451.5005.067.59[0.1 - 1]
payoutRatioTTM0-1.00000[0 - 1]
currentRatioTTM3.200.80010.008.00[1 - 3]
quickRatioTTM2.780.80010.008.00[0.8 - 2.5]
cashRatioTTM2.581.50010.0010.00[0.2 - 2]
debtRatioTTM0.0444-1.5009.26-10.00[0 - 0.6]
interestCoverageTTM33.771.00010.0010.00[3 - 30]
operatingCashFlowPerShareTTM-0.8792.00-0.293-0.586[0 - 30]
freeCashFlowPerShareTTM-0.9092.00-0.455-0.909[0 - 20]
debtEquityRatioTTM0.0621-1.5009.75-10.00[0 - 2.5]
grossProfitMarginTTM-1.2031.000-10.00-10.00[0.2 - 0.8]
operatingProfitMarginTTM-0.3481.000-8.96-8.96[0.1 - 0.6]
cashFlowToDebtRatioTTM-10.101.000-10.00-10.00[0.2 - 2]
assetTurnoverTTM0.1290.800-2.47-1.977[0.5 - 2]
Total Score5.02

Dividend Growth Score (DGS)

RatioActual ValueWeightNormalized ValueScoreRange
peRatioTTM1.6051.0009.940[1 - 100]
returnOnEquityTTM0.5452.506.827.59[0.1 - 1.5]
freeCashFlowPerShareTTM-0.9092.00-0.303-0.909[0 - 30]
dividendYielPercentageTTM01.50000[0 - 0.4]
operatingCashFlowPerShareTTM-0.8792.00-0.293-0.586[0 - 30]
payoutRatioTTM01.50000[0 - 1]
pegRatioTTM-0.009121.500-3.390[0.5 - 2]
operatingCashFlowSalesRatioTTM-3.471.000-10.000[0.1 - 0.5]
Total Score0.366

Enzo Biochem Inc

Enzo Biochem, Inc., an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates through three segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics. The Life Sciences Products segment develops, manufactures, and markets products and tools to clinical research, drug development, and bioscience research customers. It offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. This segment also provides its products to scientific experts in the fields of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury. The Clinical Laboratory Services segment provides molecular and other clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, and search for an otherwise undiagnosed condition. It operates a full-service clinical laboratory in Farmingdale, New York; a network of 30 patient service centers in New York and New Jersey; and a free-standing ‘STAT' or rapid response laboratories in New York City and Connecticut, as well as a full-service phlebotomy center and an in-house logistics department. The Therapeutics segment develops novel approaches in the areas of gastrointestinal, infectious, ophthalmic, and metabolic diseases. It markets its products and services through its direct sales force and a network of distributors in the United States and internationally. The company was founded in 1976 and is headquartered in New York, New York.

Apie Signalai gyvai

Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.

Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.